These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32479083)

  • 1. Identification of
    Zhu Y; Ma Y; Zu W; Song J; Wang H; Zhong Y; Li H; Zhang Y; Gao Q; Kong B; Xu J; Jiang F; Wang X; Li S; Liu C; Liu H; Lu T; Chen Y
    J Med Chem; 2020 Jul; 63(13):6748-6773. PubMed ID: 32479083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
    Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
    J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
    Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
    Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
    Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R
    J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.
    Chough C; Joung M; Lee S; Lee J; Kim JH; Kim BM
    Bioorg Med Chem; 2018 May; 26(8):1495-1510. PubMed ID: 29452839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting NF-κB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures.
    Li K; McGee LR; Fisher B; Sudom A; Liu J; Rubenstein SM; Anwer MK; Cushing TD; Shin Y; Ayres M; Lee F; Eksterowicz J; Faulder P; Waszkowycz B; Plotnikova O; Farrelly E; Xiao SH; Chen G; Wang Z
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1238-44. PubMed ID: 23374866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
    Tan H; Liu Y; Gong C; Zhang J; Huang J; Zhang Q
    Eur J Med Chem; 2021 Nov; 223():113670. PubMed ID: 34214842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.
    Wang S; Midgley CA; Scaërou F; Grabarek JB; Griffiths G; Jackson W; Kontopidis G; McClue SJ; McInnes C; Meades C; Mezna M; Plater A; Stuart I; Thomas MP; Wood G; Clarke RG; Blake DG; Zheleva DI; Lane DP; Jackson RC; Glover DM; Fischer PM
    J Med Chem; 2010 Jun; 53(11):4367-78. PubMed ID: 20462263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
    Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological activity of N
    Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
    Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.
    Ding X; Stasi LP; Ho MH; Zhao B; Wang H; Long K; Xu Q; Sang Y; Sun C; Hu H; Yu H; Wan Z; Wang L; Edge C; Liu Q; Li Y; Dong K; Guan X; Tattersall FD; Reith AD; Ren F
    Bioorg Med Chem Lett; 2018 May; 28(9):1615-1620. PubMed ID: 29588215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).
    McHardy T; Caldwell JJ; Cheung KM; Hunter LJ; Taylor K; Rowlands M; Ruddle R; Henley A; de Haven Brandon A; Valenti M; Davies TG; Fazal L; Seavers L; Raynaud FI; Eccles SA; Aherne GW; Garrett MD; Collins I
    J Med Chem; 2010 Mar; 53(5):2239-49. PubMed ID: 20151677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aryl amide derivatives of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives useful as ASK1 inhibitors, an evaluation of WO2012080735.
    Norman P
    Expert Opin Ther Pat; 2012 Dec; 22(12):1479-83. PubMed ID: 22917158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
    Musumeci F; Sanna M; Grossi G; Brullo C; Fallacara AL; Schenone S
    Curr Med Chem; 2017; 24(19):2059-2085. PubMed ID: 28266267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.
    Thorarensen A; Dowty ME; Banker ME; Juba B; Jussif J; Lin T; Vincent F; Czerwinski RM; Casimiro-Garcia A; Unwalla R; Trujillo JI; Liang S; Balbo P; Che Y; Gilbert AM; Brown MF; Hayward M; Montgomery J; Leung L; Yang X; Soucy S; Hegen M; Coe J; Langille J; Vajdos F; Chrencik J; Telliez JB
    J Med Chem; 2017 Mar; 60(5):1971-1993. PubMed ID: 28139931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. X-ray Crystal Structure-Guided Design and Optimization of 7
    Lee Y; Kim H; Kim H; Cho HY; Jee JG; Seo KA; Son JB; Ko E; Choi HG; Kim ND; Kim I
    J Med Chem; 2021 May; 64(10):6985-6995. PubMed ID: 33942608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of new NIK inhibitors by discriminatory analysis-based molecular docking and biological evaluation.
    Cheng G; Mei XB; Yan YY; Chen J; Zhang B; Li J; Dong XW; Lin NM; Zhou YB
    Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800374. PubMed ID: 31116887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.